Clinical Research of Chronic Hepatitis B Treated with Integrative Chinese and Western Medicine

HAO Da-lin

您当前的位置：

首页 >

文章列表页 >

Clinical Research of Chronic Hepatitis B Treated with Integrative Chinese and Western Medicine

更新时间：2024-01-04

- Clinical Research of Chronic Hepatitis B Treated with Integrative Chinese and Western Medicine
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 18, Issue 24, Pages: 330-333(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012
- 稿件说明：
移动端阅览
HAO Da-lin. Clinical Research of Chronic Hepatitis B Treated with Integrative Chinese and Western Medicine[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(24): 330-333.
DOI：

HAO Da-lin. Clinical Research of Chronic Hepatitis B Treated with Integrative Chinese and Western Medicine[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(24): 330-333. DOI：

摘要

目的: 探讨中西医结合方案治疗慢性乙型肝炎(CHB)的临床疗效。方法: 76例CHB患者随机分成观察组39例和对照组37例。对照组采用派罗欣180 μg/次

1次/周

观察组在此基础上根据不同中医证候加用十味溪黄草颗粒或人参健脾丸。疗程均为48周。观测两组肝功能、中医证候积分、HBV-DNA定量及乙肝病毒血清标志物。结果: 疗后24

48周观察组血清HBV-DNA水平低于对照组(P<0.05

P<0.01);疗后12

48周观察组中医证候积分明显低于对照组(P<0.01);疗后24

48周观察组门冬氨酸氨基转移酶(AST)

丙氨酸氨基转移酶(ALT)

总胆红素(TBil)水平低于对照组(P<0.05

P<0.01);疗后48周观察组肝功复常率及HBV-DNA转阴率均优于对照组(P<0.05)。结论: 中西医结合治疗CHB较单纯的西医治疗有更明显的临床优势

值得推广使用。

Abstract

Objective:To Investigate the clinical effect on chronic viral hepatitis B(CHB)treated with integrative Chinese and western medicine. Method: Sixty cases of chronic viral hepatitis B were randomized into observation group (39 cases) and control group (37 cases). The control group was treated with pegasys 180 μg/times

1time/week

subcutaneously; the observation group was treated with the Shiwei Xihuangcao granules or Renshen Jianpi wan according to the different traditional Chinese medicine (TCM) symptoms on the basis of the control group. The course of treatment was 48 weeks. Liver function

TCM syndrome score

HBV-DNA quantitative and HBV markers of two groups were observed. Result: The level of aspartate aminotransferase (AST)

alanine transaminase (ALT)

total bilirubin (TBil) of the observation group was lower than that of the control group after 24

48 weeks treatment (P<0.05

P<0.01). The TCM syndrome score of the observation group was lower than the control group after 12

48 weeks treatment(P<0.01). The level of serum HBV-DNA of the observation group was lower than the control group after 24

48 weeks treatment (P<0.05

P<0.01). The Liver function normalization rate and HBV-DNA negative rate of the observation group were better than the control group after 48 weeks treatment(P<0.05). Conclusion: Integrative treatment of CHB has more obvious clinical advantages than the simple treatment of western medicine and worth to promote to use clinically.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of Tiaogan Huaxian Pills in Prevention and Treatment of Hepatic Fibrosis in Hepatitis B and Its Effect on Diffusion-weighted Imaging

Clinical Efficacy of Zhuyuwan in Treatment of Hyperlipidemia with Syndrome of Phlegm Turbidity and Obstruction

Clinical Randomized Controlled Trial of Traditional Chinese Medicine Compound Shenlong Decoction Granules in Treatment of Idiopathic Pulmonary Fibrosis

Clinical Efficacy of Jinwei Pingchuan Decoction in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Phlegm-heat Obstruction in Lung Syndrome

Related Author

DAI Haiyang

HUANG Guye

XU Wencong

SHEN Yan

LI Yuan

YANG Lele

LUO Danmei

CHEN Jiao

Related Institution

Guangxi University of Chinese Medicine

The First Affiliated Hospital of Guangxi University of Chinese Medicine

Hospital of Chengdu University of Traditional Chinese Medicine （TCM）

Chengdu University of TCM

Liaoning University of Traditional Chinese Medicine（TCM）

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰